TP53 and acute myeloid leukemia: Table 1 summarizes the findings across phase I–III trials, post hoc analyses, regulatory reviews, and real-world evidence (RWE) cohorts, including recent genomic and MRD-integrated datasets. The table highlights variations in study design, patient populations (therapy-related AML, AML-MRC, TP53-mutated, secondary-type mutations), dosing schedules, response rates, survival outcomes, and transplant feasibility.